News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Refractec, Inc. Promotes Thomas G. Frinzi To Chief Executive Officer
June 7, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Ophthalmic device manufacturer Refractec, Inc. today announced the promotion of Thomas G. Frinzi to the position of chief executive officer. Frinzi replaces Mitch Campbell who has left the company to pursue other entrepreneurial ventures.
Twitter
LinkedIn
Facebook
Email
Print
People
MORE ON THIS TOPIC
Drug Development
Dren Bio lands $350M to push rare blood cancer therapy toward market
October 29, 2026
·
2 min read
·
Gabrielle Masson
Earnings
Lilly’s guidance has jumped by $10B as GLP-1 sales keep blowing past expectations
October 29, 2026
·
3 min read
·
Annalee Armstrong
Earnings
Merck looks ahead to ‘another year of investment’ as Keytruda cliff looms
October 29, 2026
·
4 min read
·
Heather McKenzie
Earnings
BMS drops Prothena-partnered neuro drug, sales outlook improves on a Q3 beat
October 29, 2026
·
4 min read
·
Gabrielle Masson
